Table 9. Progression Free Survival profile by Log-Rank analysis.

Factors		PFS
		NSCLC				ESOC				CRC				H&NC				GC
		PFS (day)	95% CI		p	PFS (day)	95% CI		p	PFS (day)	95% CI		p	PFS (day)	95% CI		p	PFS (day)	95% CI		p
General PFS		173	33.1	312.9		196	0	411		217	181	253		198	102	294		142	18.8	265
Sex	Male	173	112	233.9	0.23	196	0	411	NA	210	170	250	0.76	302	0	635	0.04	.	.	.	0.03
	Female	89	76.2	101.8		NA	NA	NA		225	114	336		127	31.4	223		127	42.4	212
Age	<60y	104	21.9	186.1	0.04	196	0	408	0.56	210	78.2	342	0.59	198	0	415	0.48	253	0	517	0.62
	≥60y	521								225	171	279		151	61.6	240		127	12.5	242
Surgery	NO	98	0	227.6	0.34	1536			0.10	171	107	235	0.03	169	96	242	0.62	142	106	178	0.80
	YES	211	80.6	341.4		109	0	244		225	188	262		228	0	466		253	30.3	476
Nimotuzumab frequency	≤6	89	40.5	137.5	0.27	109	28.2	190	0.07	171	4.11	338	0.01	228	72.7	383	0.85	.	.	.	0.06
	>6	211	146	275.8		423	83.2	763		225	185	265		198	36.8	359		253	103	403
Nimotuzumab doses (mg/w)	≤200	264	81.5	446.5	0.55	141			0.58	163	75.5	251	0.45	399	85.4	713	0.30	.	.	.	0.06
	>200	173	40.1	305.9		423	80.4	766	217		174	260		169	105	233		253	103	403

Bold text indicates statistically significant (P-values <0.05)